Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

• Zymeworks Inc (NASDAQ: ZYME) presented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors.

• The data were presented at the European Society for Medical Oncology Annual Congress.

• A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy.

• Also Read: Zymeworks Turns Down All Blue's Hostile Bid.

• At the time of the analysis, the maximum tolerated dose had not yet been reached.

• In the trial, zanidatamab zovodotin was shown to have a manageable safety profile, with the majority of adverse events being mild or moderate.

• In patients with HER2-positive cancers treated with zanidatamab zovodotin at 2.5 mg/kg Q3W, the confirmed objective response rate was 31%, and the disease control rate was 72%.

• The Phase 1 trial continues to enroll patients to study safety. The company expects to present the results of this dosing regimen at a medical meeting in 2023.

• Price Action: ZYME shares are up 0.20% at $4.95 during the market session on the last check Tuesday.

See more from Benzinga

• After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff

• Just After Encouraging Colorectal Cancer Data, Cardiff Oncology Shares Slump, Read Why

• Trump Says Putin's Ukraine Invasion Will Result In World War 3: 'Watch What's Going To Happen With China

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.